Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bayer Licenses Drug From Isis Pharma
by Ann M. Thayer
May 11, 2015
| A version of this story appeared in
Volume 93, Issue 19
Bayer HealthCare will pay Isis Pharmaceuticals up to $155 million to develop and commercialize ISIS-FXIRx for the prevention of thrombosis, or clotting disorders. Isis will receive $100 million up front and the rest if the drug advances following a Phase II study in patients with compromised kidney function. ISIS-FXIRx is an antisense drug that inhibits the production of Factor XI, a clotting factor produced in the liver. Bayer also plans to evaluate ISIS-FXIRx in patients for whom current anticoagulants cannot be used.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X